Shape-Specific Gold Nanoparticles for Multiplex Biosensing Applications
The biosensing field faces a significant challenge in efficiently detecting multiple analytes in a single diagnostic sample in order to compete with other established multiplex molecular diagnostic technologies such as PCR and ELISA. In response, we have developed a colorimetric nanobiosensor based on multiple morphological forms of functionalized gold nanoparticles (AuNPs) for the simultaneous detection of the influenza virus and SARS-CoV-2 virus. Gold nanospheres (GNSp) were modified with oligonucleotides specific for the influenza A virus, while gold nanoshells (GNSh) were modified with oligonucleotides specific for the SARS-CoV-2 virus. In the presence of their respective targets, AuNPs remain stable due to DNA-DNA interactions; conversely, in the absence of targets, AuNPs aggregate. Consequently, the hybrid system exhibits an indigo color with the SARS-CoV-2 target, a blue color with the Influenza A target, and a purple color with both targets, visible to the naked eye. Analytical sensitivity was 100 nM, and no cross-reactivity was observed with potentially confounding pathogens. This approach holds great promise for the simultaneous identification of multiple pathogens in a rapid manner without the need for equipment or trained personnel.
Authors
- Charles H. Lawrie (ORCID: https://orcid.org/0000-0002-8882-1131)
- Yuan Peng (ORCID: https://orcid.org/0000-0002-4536-4030)
- Mathias Charconnet (ORCID: https://orcid.org/0000-0003-2786-8750)
- Shixi Zhang (ORCID: https://orcid.org/0000-0001-6649-622X)
- Yuhan Zhang (ORCID: https://orcid.org/0009-0009-0505-6322)
- Lei Zhang (ORCID: https://orcid.org/0000-0003-3765-7324)
- Jiaye Jiang
Institutions
- Ikerbasque (ES)
- Shanghai University (CN)
- University of Oxford (GB)
Publication Details
- Journal
- ACS Omega
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1021/acsomega.4c04385
- Citations
- 6
- Primary Topic
- Biosensors and Analytical Detection
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- European Commission
- Instituto de Salud Carlos III